A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome. Issue 1 (January 2020) - Kiaie, Nasim
Highlights: Atherosclerotic cardiovascular disease (ASCVD) is a major cause of mortality and morbidity worldwide. Improved visualization of early atherosclerosis and better management of residual risk can reduce ASCVD burden. Recent research has investigated the potential of biomaterials and nanomedicines in meeting this demand. Liposomes have a wide range of applications in both imaging and treatment of atherosclerosis. We review the scientific and clinical evidence relating to the use of liposomes in the context of ASCVD. Abstract : The consequences of atherosclerotic cardiovascular disease (ASCVD) include myocardial infarction, ischemic stroke, and angina pectoris, which are major causes of mortality and morbidity worldwide. Despite current therapeutic strategies to reduce risk, patients still experience the consequences of ASCVD. Consequently, a current goal is to enhance visualization of early atherosclerotic lesions to improve residual ASCVD risk. The uses of liposomes, in the context of ASCVD, can include as contrast agents for imaging techniques, as well as for the delivery of antiatherosclerotic drugs, genes, and cells to established sites of plaque. Additionally, liposomes have a role as vaccine adjuvants against mediators of atherosclerosis. Here. we review the scientific and clinical evidence relating to the use of liposomes in the diagnosis and management of ASCVD. Teaser: This review describes the experimental and clinical evidence for the use of liposomes in the diagnosis and management of atherosclerotic cardiovascular disease.